vs
通用电气医疗（OPCH）与维谛技术（VRT）财务数据对比。点击上方公司名可切换其他公司
维谛技术的季度营收约是通用电气医疗的1.8倍（$2.6B vs $1.4B），维谛技术净利率更高（14.7% vs 3.6%，领先11.1%），维谛技术同比增速更快（30.1% vs 12.2%），维谛技术自由现金流更多（$652.8M vs $130.2M），过去两年维谛技术的营收复合增速更高（16.5% vs 13.0%）
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
维谛技术（Vertiv）是一家美国跨国企业，专注于为数据中心、通信网络、商业及工业场景提供关键基础设施及配套服务，旗下方案可有效保障各行业客户关键业务系统的稳定高效运行。
OPCH vs VRT — 直观对比
营收规模更大
VRT
是对方的1.8倍
$1.4B
营收增速更快
VRT
高出17.9%
12.2%
净利率更高
VRT
高出11.1%
3.6%
自由现金流更多
VRT
多$522.6M
$130.2M
两年增速更快
VRT
近两年复合增速
13.0%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $2.6B |
| 净利润 | $51.8M | $390.1M |
| 毛利率 | 19.0% | 37.7% |
| 营业利润率 | 5.9% | — |
| 净利率 | 3.6% | 14.7% |
| 营收同比 | 12.2% | 30.1% |
| 净利润同比 | -3.8% | 137.1% |
| 每股收益（稀释后） | $0.32 | $0.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPCHVRT
| Q1 26 | — | $2.6B | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | $1.4B | $2.7B | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.2B | $2.0B |
净利润OPCHVRT
| Q1 26 | — | $390.1M | ||
| Q4 25 | — | $445.6M | ||
| Q3 25 | $51.8M | $398.5M | ||
| Q2 25 | $50.5M | $324.2M | ||
| Q1 25 | $46.7M | $164.5M | ||
| Q4 24 | $60.1M | $147.0M | ||
| Q3 24 | $53.9M | $176.6M | ||
| Q2 24 | $53.0M | $178.1M |
毛利率OPCHVRT
| Q1 26 | — | 37.7% | ||
| Q4 25 | — | 38.9% | ||
| Q3 25 | 19.0% | 37.8% | ||
| Q2 25 | 19.0% | 34.0% | ||
| Q1 25 | 19.7% | 33.7% | ||
| Q4 24 | 21.3% | 37.1% | ||
| Q3 24 | 20.1% | 36.5% | ||
| Q2 24 | 20.3% | 38.0% |
营业利润率OPCHVRT
| Q1 26 | — | — | ||
| Q4 25 | — | 20.1% | ||
| Q3 25 | 5.9% | 19.3% | ||
| Q2 25 | 5.8% | 16.8% | ||
| Q1 25 | 5.9% | 14.3% | ||
| Q4 24 | 6.9% | 19.5% | ||
| Q3 24 | 6.7% | 17.9% | ||
| Q2 24 | 6.6% | 17.2% |
净利率OPCHVRT
| Q1 26 | — | 14.7% | ||
| Q4 25 | — | 15.5% | ||
| Q3 25 | 3.6% | 14.9% | ||
| Q2 25 | 3.6% | 12.3% | ||
| Q1 25 | 3.5% | 8.1% | ||
| Q4 24 | 4.8% | 6.3% | ||
| Q3 24 | 4.2% | 8.5% | ||
| Q2 24 | 4.3% | 9.1% |
每股收益（稀释后）OPCHVRT
| Q1 26 | — | $0.99 | ||
| Q4 25 | — | $1.14 | ||
| Q3 25 | $0.32 | $1.02 | ||
| Q2 25 | $0.31 | $0.83 | ||
| Q1 25 | $0.28 | $0.42 | ||
| Q4 24 | $0.36 | $0.38 | ||
| Q3 24 | $0.31 | $0.46 | ||
| Q2 24 | $0.30 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $309.8M | $2.5B |
| 总债务越低越好 | $1.2B | $0 |
| 股东权益账面价值 | $1.4B | $4.2B |
| 总资产 | $3.5B | $13.4B |
| 负债/权益比越低杠杆越低 | 0.86× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资OPCHVRT
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | $1.7B | ||
| Q3 25 | $309.8M | $1.4B | ||
| Q2 25 | $198.8M | $1.6B | ||
| Q1 25 | $171.4M | $1.5B | ||
| Q4 24 | $412.6M | $1.2B | ||
| Q3 24 | $483.0M | $908.7M | ||
| Q2 24 | $376.9M | $579.7M |
总债务OPCHVRT
| Q1 26 | — | $0 | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | $1.2B | $2.9B | ||
| Q2 25 | $1.1B | $2.9B | ||
| Q1 25 | $1.1B | $2.9B | ||
| Q4 24 | $1.1B | $2.9B | ||
| Q3 24 | $1.1B | $2.9B | ||
| Q2 24 | $1.1B | $2.9B |
股东权益OPCHVRT
| Q1 26 | — | $4.2B | ||
| Q4 25 | — | $3.9B | ||
| Q3 25 | $1.4B | $3.5B | ||
| Q2 25 | $1.4B | $3.1B | ||
| Q1 25 | $1.4B | $2.7B | ||
| Q4 24 | $1.4B | $2.4B | ||
| Q3 24 | $1.4B | $1.8B | ||
| Q2 24 | $1.4B | $1.5B |
总资产OPCHVRT
| Q1 26 | — | $13.4B | ||
| Q4 25 | — | $12.2B | ||
| Q3 25 | $3.5B | $10.8B | ||
| Q2 25 | $3.4B | $10.4B | ||
| Q1 25 | $3.3B | $9.5B | ||
| Q4 24 | $3.4B | $9.1B | ||
| Q3 24 | $3.4B | $8.9B | ||
| Q2 24 | $3.3B | $8.1B |
负债/权益比OPCHVRT
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.74× | ||
| Q3 25 | 0.86× | 0.83× | ||
| Q2 25 | 0.82× | 0.93× | ||
| Q1 25 | 0.82× | 1.10× | ||
| Q4 24 | 0.79× | 1.20× | ||
| Q3 24 | 0.78× | 1.62× | ||
| Q2 24 | 0.79× | 1.91× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $139.4M | — |
| 自由现金流经营现金流 - 资本支出 | $130.2M | $652.8M |
| 自由现金流率自由现金流/营收 | 9.1% | 24.6% |
| 资本支出强度资本支出/营收 | 0.6% | 4.2% |
| 现金转化率经营现金流/净利润 | 2.69× | — |
| 过去12个月自由现金流最近4个季度 | $220.7M | $2.3B |
8季度趋势，按日历期对齐
经营现金流OPCHVRT
| Q1 26 | — | — | ||
| Q4 25 | — | $978.9M | ||
| Q3 25 | $139.4M | $508.7M | ||
| Q2 25 | $90.3M | $322.9M | ||
| Q1 25 | $-7.2M | $303.3M | ||
| Q4 24 | $36.1M | $425.2M | ||
| Q3 24 | $160.4M | $378.2M | ||
| Q2 24 | $195.7M | $378.4M |
自由现金流OPCHVRT
| Q1 26 | — | $652.8M | ||
| Q4 25 | — | $885.6M | ||
| Q3 25 | $130.2M | $463.5M | ||
| Q2 25 | $81.2M | $277.9M | ||
| Q1 25 | $-16.6M | $266.8M | ||
| Q4 24 | $25.8M | $364.5M | ||
| Q3 24 | $150.7M | $341.8M | ||
| Q2 24 | $185.9M | $344.3M |
自由现金流率OPCHVRT
| Q1 26 | — | 24.6% | ||
| Q4 25 | — | 30.8% | ||
| Q3 25 | 9.1% | 17.3% | ||
| Q2 25 | 5.7% | 10.5% | ||
| Q1 25 | -1.2% | 13.1% | ||
| Q4 24 | 2.0% | 15.5% | ||
| Q3 24 | 11.8% | 16.5% | ||
| Q2 24 | 15.1% | 17.6% |
资本支出强度OPCHVRT
| Q1 26 | — | 4.2% | ||
| Q4 25 | — | 3.2% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | 0.6% | 1.7% | ||
| Q1 25 | 0.7% | 1.8% | ||
| Q4 24 | 0.8% | 2.6% | ||
| Q3 24 | 0.8% | 1.8% | ||
| Q2 24 | 0.8% | 1.7% |
现金转化率OPCHVRT
| Q1 26 | — | — | ||
| Q4 25 | — | 2.20× | ||
| Q3 25 | 2.69× | 1.28× | ||
| Q2 25 | 1.79× | 1.00× | ||
| Q1 25 | -0.15× | 1.84× | ||
| Q4 24 | 0.60× | 2.89× | ||
| Q3 24 | 2.98× | 2.14× | ||
| Q2 24 | 3.69× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
VRT
暂无分部数据
